Aurobindo Pharma’s arm gets USFDA approval for Bortezomib for injection

04 May 2022 Evaluate

Aurobindo Pharma’s wholly owned subsidiary company -- Eugia Pharma Specialties has received final approval from US Food & Drug Administration (USFDA) to manufacture and market Bortezomib for injection, 3.5 mg. Bortezomib for Injection, 3.5 mg/vial (Single-Dose Vial) to be bioequivalent and therapeutically equivalent to the Velcade for Injection 3.5 mg/vial, of Takeda Pharmaceuticals U.S.A. Inc. The product is being launched immediately. The approved product has a market size of $1172 million for the twelve months ending March 2022, according to IQVIA.

This is the 136th ANDA (including 7 tentative approvals) to be out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes)

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1184.20 3.00 (0.25%)
01-Jan-2026 14:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.65
Dr. Reddys Lab 1250.90
Cipla 1499.55
Zydus Lifesciences 913.30
Lupin 2099.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×